Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
— The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 — Safety in GCA patients was consistent with known safety profile of Cosentyx® (secukinumab)1 Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with […]